Sigyn Therapeutics (SIGY) Stock Price, News & Analysis

Company Overview

Sigyn Therapeutics, Inc., a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. In addition, it develops ChemoPrep to enhance the tumor site delivery of chemotherapy; ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis; and ImmunePrep to enhance the potential efficacy of immunotherapeutic antibodies. Sigyn Therapeutics, Inc. was founded in 2019 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $0.03 to $0.03
• 50-Day Range: $0.02 to $0.05
• 52-Week Range: $0.01 to $5.00
• Volume: 6,000 shs
• Average Volume: 31,089 shs
• Market Capitalization: $75.95 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Sigyn Therapeutics Stock Analysis - MarketRank™

Sigyn Therapeutics scored higher than 28% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Sigyn Therapeutics.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Sigyn Therapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sigyn Therapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.27% of the float of Sigyn Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Sigyn Therapeutics has a short interest ratio ("days to cover") of 0.01, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sigyn Therapeutics has recently decreased by 78.84%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sigyn Therapeutics does not currently pay a dividend.

Dividend Growth

Sigyn Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: N/A

News Sentiment

Sigyn Therapeutics has a news sentiment score of 1.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.91 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Sigyn Therapeutics this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sigyn Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

78.46% of the stock of Sigyn Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

10.01% of the stock of Sigyn Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 7/16/2026
• Today: 7/24/2026
• Next Earnings (Estimated): 8/18/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Medical Equipment
• Current Symbol: OTCMKTS:SIGY
• CIK: 1642159
• Web: www.sigyntherapeutics.com
• Phone: (619) 353-0800
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.78) per share
• Price / Book: -0.01

Miscellaneous

• Outstanding Shares: 2,540,000
• Free Float: 548,000
• Market Cap: $75.95 thousand
• Optionable: Not Optionable
• Beta: -0.08